Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-07-04 20:50:00
Oslo, Norway, July 4, 2022 - Nykode Therapeutics ASA (Oslo Stock Exchange (OSE):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced that 200,000
share options have been granted to Klaus Edvardsen in connection with his
appointment as Chief Development Officer. The share options will have a strike
price of NOK 31.11 per share, have a five-year term and will vest equally over a
four-year vesting period.
Please see further details in attached document.